A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 Oral Solution in the Treatment of Subjects With Essential Tremor
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs SAGE 217 (Primary)
- Indications Essential tremor
- Focus Therapeutic Use
- Sponsors Sage Therapeutics
- 13 Oct 2017 Planned number of patients changed from 60 to 30.
- 01 Mar 2017 Planned number of patients changed from 80 to 60.
- 13 Dec 2016 According to a Sage Therapeutics media release, trial sites are open for recruitment and are expected to be dosed imminently in this trial.